PE-22-28

Overview

PE-22-28 is a synthetic 8-amino acid peptide designed to block the TREK-1 potassium channel — one of the most studied molecular targets in antidepressant research. It's derived from the C-terminal fragment of PACAP 1–38 (pituitary adenylyl cyclase-activating polypeptide), the same parent molecule that gave rise to spadin, a longer 17-amino acid peptide that researchers have been studying for depression since around 2010.

The short version of why this matters: TREK-1 is a background potassium channel that keeps neurons quieter than they should be in people with depression. Block it, and serotonergic signaling improves — fast, in animal models, without the weeks-long delay you see with SSRIs. PE-22-28 was developed specifically to see whether you could get that same effect with a much smaller, more optimized molecule.[1]

Everything here is preclinical. There are no human trials as of early 2026. But the mechanism is genuinely interesting, and the animal data is compelling enough that this peptide has attracted serious research attention.

Mechanism of Action

TREK-1 channel blockade; PAC1 receptor activation; cAMP accumulation; CREB phosphorylation

Start with TREK-1. It's a two-pore domain potassium channel — a type of background channel that's always partially open, constantly leaking potassium out of neurons and keeping their resting membrane potential more negative (more inhibited) than it would otherwise be. In serotonergic neurons specifically, high TREK-1 activity correlates with reduced firing and lower serotonin release. Knock out TREK-1 in mice and they show antidepressant and anxiolytic behavior. Block it pharmacologically and you get a similar effect.[1]

PE-22-28 binds to TREK-1 and inhibits that potassium leak. The result is increased neuronal excitability in the relevant circuits — more serotonin release, faster signaling, and behavioral effects in animal models that look like antidepressant activity without the latency of SSRI treatment.

The PAC1 receptor piece adds another layer. PAC1 is a G-protein coupled receptor that responds to PACAP — the same parent molecule PE-22-28 is derived from. When PE-22-28 activates PAC1, it triggers adenylyl cyclase, which converts ATP to cAMP (cyclic adenosine monophosphate). Elevated cAMP then activates protein kinase A, which phosphorylates CREB. Phosphorylated CREB turns on genes involved in neuronal survival, synaptic strengthening, and the production of neurotrophic factors like BDNF (brain-derived neurotrophic factor). This is the molecular pathway that underlies learning, memory formation, and much of what we mean when we talk about "synaptic plasticity."

Whether PE-22-28's effects on cognition and neuroprotection are primarily TREK-1 mediated, PAC1 mediated, or some combination of both hasn't been cleanly separated in the available research — PE-22-28 has not been characterized in published research; the mechanistic basis of any potential cognitive or neuroprotective effects remains unknown.

What the Evidence Shows

The honest answer is: the evidence is entirely preclinical. Every published study involves animal models — primarily rodents — and in-vitro work. There are no Phase 1, Phase 2, or Phase 3 human trials registered or completed for PE-22-28 as of early 2026.

The most directly relevant published work comes from a 2017 paper in Frontiers in Pharmacology examining shortened spadin analogs, of which PE-22-28 is one.[1] That paper characterized TREK-1 inhibitory activity across a series of truncated peptides derived from the spadin sequence, testing which amino acid segments were necessary for channel blockade. PE-22-28 was identified as a candidate within this series showing TREK-1 inhibition.

The broader body of evidence supporting the TREK-1 mechanism includes work on spadin itself going back to approximately 2010, establishing the channel's role in serotonergic function and the antidepressant-like behavioral effects of blocking it in rodent models. PE-22-28 inherits that mechanistic rationale, but the specific behavioral and neurochemical data for the 8-amino acid version — separate from the longer spadin series — is limited in the publicly available literature, practitioner-reported, not confirmed in published clinical trials.

Side Effects
There is no human side effect data for PE-22-28. None. The compound has not been administered to people in any documented clinical setting, so any list of human adverse effects would be fabricated.

What animal studies can tell you is limited, but animal study data for PE-22-28 is not available in the public literature; the safety profile in any species has not been established or published — and rodent tolerability does not predict human tolerability in any reliable way, particularly for CNS-active peptides where species differences in receptor distribution and blood-brain barrier penetration are significant.

PE-22-28 has no established human safety data. If you encounter vendors or practitioners claiming a known side effect profile for this compound in humans, treat that as a red flag — it means they're extrapolating from animal data or fabricating information. The honest answer is that we don't know what the human side effect profile looks like.